SCHEMBL2990950

SCHEMBL2990950

CCOC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1c1cccc2ncccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.64
ALDH1A1 P00352 9/20 0.64
HSD17B10 Q99714 9/20 0.64
HPGD P15428 6/20 0.64
CASP1 P29466 5/20 0.64
CASP7 P55210 5/20 0.64
GAA P10253 5/20 0.64
TSHR P16473 1/20 0.58
BAP1 Q92560 1/20 0.57
HTT P42858 1/20 0.55
MAPK1 P28482 2/20 0.53
MAPT P10636 1/20 0.53
ALOX15 P16050 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999620 0.94 KDM4E (0.65) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL2990955 0.87 KDM4E (0.59) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL4260123 0.86 KDM4E (0.67) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL3249662 0.84 KDM4E (0.69) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL2999625 0.81 KDM4E (0.61) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL2992328 0.81 KDM4E (0.65) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL10953920 0.79 KDM4E (0.77) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL10704884 0.79 KDM4E (0.62) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL3325553 0.78 ALDH1A1 (1.00) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL3004453 0.78 KDM4E (0.64) KDM4EALDH1A1HSD17B10HPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.